Stemline Therapeutics Inc (NASDAQ:STML) Receives $25.00 Consensus Target Price from Analysts

Shares of Stemline Therapeutics Inc (NASDAQ:STML) have earned a consensus recommendation of “Buy” from the nine brokerages that are currently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $25.00.

Several analysts have recently commented on STML shares. Zacks Investment Research cut Stemline Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 30th. BidaskClub upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of Stemline Therapeutics in a report on Monday, September 30th. Cowen restated a “buy” rating on shares of Stemline Therapeutics in a report on Wednesday, September 18th. Finally, Wedbush upgraded Stemline Therapeutics from a “neutral” rating to an “outperform” rating in a report on Friday, August 2nd.

Shares of NASDAQ STML traded down $1.19 during trading hours on Tuesday, reaching $9.25. The stock had a trading volume of 2,655,100 shares, compared to its average volume of 625,907. The business’s fifty day moving average is $9.85 and its two-hundred day moving average is $12.94. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.71 and a quick ratio of 4.57. The company has a market cap of $486.37 million, a price-to-earnings ratio of -3.09 and a beta of 1.35. Stemline Therapeutics has a twelve month low of $7.82 and a twelve month high of $18.22.

Stemline Therapeutics (NASDAQ:STML) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.08. The business had revenue of $13.33 million for the quarter, compared to the consensus estimate of $13.40 million. Sell-side analysts forecast that Stemline Therapeutics will post -1.99 earnings per share for the current fiscal year.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

In related news, CEO Ivan Bergstein sold 35,010 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $14.73, for a total value of $515,697.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 13.10% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Stemline Therapeutics by 51.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,297 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 1,466 shares during the last quarter. Bank of Montreal Can bought a new position in Stemline Therapeutics in the second quarter valued at about $52,000. Steward Partners Investment Advisory LLC bought a new position in Stemline Therapeutics in the second quarter valued at about $67,000. Tower Research Capital LLC TRC boosted its holdings in Stemline Therapeutics by 364.4% in the third quarter. Tower Research Capital LLC TRC now owns 7,115 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 5,583 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in Stemline Therapeutics in the second quarter valued at about $104,000. Institutional investors and hedge funds own 83.00% of the company’s stock.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Read More: Why do companies engage in swaps?

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Leave a Reply

Your email address will not be published. Required fields are marked *

*